Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
S2308
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- NCT06337318 ↗
- Recruiting
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on S2308 (mosunetuzumab, rituximab and hyaluronidase human and 1 more in Classic Follicular Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S2308 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 3 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features
- Interventions
- Biospecimen Collection; Computed Tomography; Mosunetuzumab; Positron Emission Tomography; Rituximab; Rituximab and Hyaluronidase Human
- Arms
- Arm I (Rituximab, rituximab and hyaluronidase) · Experimental
- Arm II (Mosunetuzumab) · Experimental
- Enrollment
- 600 (estimated)
- Primary outcomes
- 3-year milestone progression free survival (PFS)
- PFS
- Sponsor
- National Cancer Institute (NCI)
- Start
- Oct 23, 2024
- Primary completion
- Mar 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06337318 · updated Oct 28, 2026